Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company specializing in immunological disease treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025.
The company's management team will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 9:10 AM EST. Additionally, they will conduct one-on-one investor meetings during the conference.
The fireside chat will be accessible via webcast, with a replay available for 90 days through the Investor Calendar section of Vera Therapeutics' website.
Vera Therapeutics (Nasdaq: VERA), un'azienda biotecnologica in fase clinica avanzata specializzata nel trattamento delle malattie immunologiche, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute TD Cowen a Boston, MA, dal 3 al 5 marzo 2025.
Il team di gestione dell'azienda parteciperà a un fireside chat programmato per martedì 4 marzo 2025, alle 9:10 AM EST. Inoltre, condurranno incontri individuali con gli investitori durante la conferenza.
Il fireside chat sarà accessibile tramite webcast, con una registrazione disponibile per 90 giorni nella sezione Calendario Investitori del sito web di Vera Therapeutics.
Vera Therapeutics (Nasdaq: VERA), una compañía biotecnológica en etapa clínica avanzada especializada en tratamientos para enfermedades inmunológicas, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen en Boston, MA, del 3 al 5 de marzo de 2025.
El equipo de gestión de la empresa participará en un fireside chat programado para el martes 4 de marzo de 2025, a las 9:10 AM EST. Además, llevarán a cabo reuniones individuales con inversores durante la conferencia.
El fireside chat será accesible a través de webcast, con una repetición disponible durante 90 días en la sección Calendario de Inversores del sitio web de Vera Therapeutics.
베라 테라퓨틱스 (Nasdaq: VERA)는 면역 질환 치료를 전문으로 하는 후기 임상 단계의 생명공학 회사로, 2025년 3월 3일부터 5일까지 매사추세츠주 보스턴에서 열리는 TD Cowen 제45회 연례 헬스케어 콘퍼런스에 참여한다고 발표했습니다.
회사의 경영진은 2025년 3월 4일 화요일 오전 9시 10분 EST에 예정된 파이어사이드 챗에 참여할 예정입니다. 또한, 회의 중에 투자자와의 일대일 미팅도 진행할 것입니다.
파이어사이드 챗은 웹캐스트를 통해 접근 가능하며, 베라 테라퓨틱스 웹사이트의 투자자 캘린더 섹션에서 90일 동안 다시 볼 수 있습니다.
Vera Therapeutics (Nasdaq: VERA), une entreprise de biotechnologie en phase clinique avancée spécialisée dans le traitement des maladies immunologiques, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston, MA, du 3 au 5 mars 2025.
L'équipe de direction de l'entreprise participera à un fireside chat prévu pour le mardi 4 mars 2025, à 9h10 EST. De plus, ils réaliseront des réunions individuelles avec des investisseurs pendant la conférence.
Le fireside chat sera accessible par webcast, avec un replay disponible pendant 90 jours dans la section Calendrier des Investisseurs du site web de Vera Therapeutics.
Vera Therapeutics (Nasdaq: VERA), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Behandlung immunologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston, MA, vom 3. bis 5. März 2025, bekannt gegeben.
Das Managementteam des Unternehmens wird an einem Fireside Chat teilnehmen, der für Dienstag, den 4. März 2025, um 9:10 Uhr EST geplant ist. Darüber hinaus werden sie während der Konferenz persönliche Investorenmeetings durchführen.
Der Fireside Chat wird über einen Webcast zugänglich sein, mit einer Wiederholung, die für 90 Tage im Bereich Investorenkalender auf der Website von Vera Therapeutics verfügbar ist.
- None.
- None.
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in one-on-one investor meetings.
Fireside Chat Details:
Date: Tuesday, March 4, 2025
Time: 9:10 AM EST
Webcast: https://wsw.com/webcast/cowen177/vera/2022522
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
When is Vera Therapeutics (VERA) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access Vera Therapeutics' (VERA) TD Cowen conference presentation?
How long will the replay of VERA's TD Cowen conference presentation be available?
What type of meetings will Vera Therapeutics (VERA) conduct at the TD Cowen conference?
